Counterx Therapeutics Inc. has executed an exclusive licensing agreement with the University of Minnesota and the University of Washington for a portfolio of novel monoclonal antibody and vaccine candidates targeting fentanyl and opioid overdose.
UCB SA and Antengene Corp. Ltd. have entered into a license agreement that grants UCB a worldwide exclusive license to further develop, manufacture and commercialize ATG-201.
